Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.

Lung cancer (Amsterdam, Netherlands) - 1 May 2026

Dong Xiaorong, Jian Hong, Huang Meijuan, Yuan Shuanghu, Zhu Zhengfei, Wu Lin, Chen Ming, Bi Nan, Pan Yi, Wang Yingyi, Lv Dongqing, Monterroso Elena Armenteros, Huang Xiangning, Mao Rui, Fu Wei, Zhao Yi, Lu Shun

Abstract excerpt

BACKGROUND: In the phase III LAURA study, osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor demonstrated statistically significant improvement in progression-free survival (PFS) versus placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) without progression during/after definitive chemoradiotherapy (CRT); PFS hazard ratio...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Chemoradiotherapy

Share to Indoles

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 41785639
DOI: 10.1016/j.lungcan.2026.109343

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.PMID 41785639Read ↗

Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study.Semantic proximity Read ↗

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.Semantic proximity Read ↗

Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China.Semantic proximity Read ↗

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.Semantic proximity Read ↗

Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.Semantic proximity Read ↗

Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH).Semantic proximity Read ↗

Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.Semantic proximity Read ↗

The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)Semantic proximity Read ↗

Outcomes of first-line osimertinib treatment for epidermal growth factor receptor-mutated non-small cell lung cancer in clinical practice settingsSemantic proximity Read ↗

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.Semantic proximity Read ↗

Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).Semantic proximity Read ↗

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.